However, it remains unclear how the convergence of these pathways drives obesity-linked cancer.[10] Although the advent of prostate specific antigen (PSA) testing has resulted in earlier prostate cancer detection, its significance in lowering prostate cancer-specific mortality is significantly less certain.[11] The impact of potential modifiers of PSA levels, with particular attention focused on obesity, may be represented in the contradictory findings of screening trials. This evidence concerns the gene KLK3 and prostate cancer.